Docket No.: 50229-267

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Peter Anthony CROOKS, et al.

Serial No.:

Group Art Unit:

Filed: June 15, 2001

Examiner:

For:

AGMATINE AND AGMATINE ANALOGS IN THE TREATMENT OF EPILEPSY,

SEIZURE AND ELECTROCONVULSIVE DISORDERS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Daniel Bucca, Ph.D.

Registration No. 42,368

600 13th Street, N.W. Washington, DC 20005-3096 (202) 756-8000 DB:prp

Date: June 15, 2001

Facsimile: (202) 756-8087

09/881215